Sanofi’s work with engineered cytokines has stumbled in the clinic, but the company isn’t throwing in the towel yet on such therapies, which hold potential for treating autoimmune diseases and cancer.

Clonal cytopenias of undetermined significance often manifest prior to myelodysplastic syndromes (MDS), and a recent study found similarities in the cytokine profiles of the distinct conditions. In ...

Sanofi’s success co-developing a blockbuster drug based on blocking the signaling of interleukin 4 and interleukin 13 (IL-4 and IL-13) makes it an ideal partner to collaborate on inflammatory ...

Cytokines are small proteins that enable cells to communicate with each other, particularly to modulate the immune system—an increasingly popular target in drug development for immunology, virology, ...